{"filing":{"accession_number":"0001193125-26-329526","cik":"0001730463","ticker":"AUTL","company_name":"Autolus Therapeutics plc","form":"8-K","filing_date":"2026-08-03","report_date":"2026-07-30","primary_document":"d156965d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1730463/000119312526329526/d156965d8k.htm"},"events":[{"id":23018,"run_id":20838,"accession_number":"0001193125-26-329526","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Autolus entered into a Note Purchase Agreement with Perceptive on July 30, 2026, creating a senior secured notes facility of up to $250 million, with an initial $75 million tranche issued on the Closing Date. The facility includes financial covenants (minimum liquidity and revenue thresholds) and security interests in substantially all assets.","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23154,"accession_number":"0001193125-26-329526","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Autolus entered into a Note Purchase Agreement with Perceptive on July 30, 2026, creating a senior secured notes facility of up to $250 million, with an initial $75 million tranche issued on the Closing Date. This is a material creation of a new direct financial obligation—a debt issuance—disclosed under Item 1.01. The facility includes interest accrual, financial covenants (minimum liquidity and revenue thresholds), and security interests in substantially all assets, making it a significant financing event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T11:02:09.082615+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23155,"accession_number":"0001193125-26-329526","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 explicitly addresses creation of a direct financial obligation. The disclosure references a \"Perceptive Senior Secured Notes Facility\" incorporated from Item 1.01, indicating issuance of new debt securities. This is a material capital event for a biopharmaceutical company and represents a direct financial obligation requiring 8-K disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T11:02:09.082615+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":23019,"run_id":20838,"accession_number":"0001193125-26-329526","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"As part of the Perceptive financing transaction, Autolus issued unregistered warrants to Perceptive, representing a dilutive equity component of the overall capital-raising activity.","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23156,"accession_number":"0001193125-26-329526","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 explicitly discloses an unregistered sale of equity securities, specifically warrants issued to Perceptive (referenced from Item 1.01). Warrant issuances are dilutive equity instruments and constitute material capital-raising activity that would affect investor assessment of ownership dilution and the registrant's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T11:02:09.082615+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23154,"accession_number":"0001193125-26-329526","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Autolus entered into a Note Purchase Agreement with Perceptive on July 30, 2026, creating a senior secured notes facility of up to $250 million, with an initial $75 million tranche issued on the Closing Date. This is a material creation of a new direct financial obligation—a debt issuance—disclosed under Item 1.01. The facility includes interest accrual, financial covenants (minimum liquidity and revenue thresholds), and security interests in substantially all assets, making it a significant financing event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T11:02:09.082615+00:00","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03"},{"id":23155,"accession_number":"0001193125-26-329526","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.03 explicitly addresses creation of a direct financial obligation. The disclosure references a \"Perceptive Senior Secured Notes Facility\" incorporated from Item 1.01, indicating issuance of new debt securities. This is a material capital event for a biopharmaceutical company and represents a direct financial obligation requiring 8-K disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T11:02:09.082615+00:00","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03"},{"id":23156,"accession_number":"0001193125-26-329526","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 explicitly discloses an unregistered sale of equity securities, specifically warrants issued to Perceptive (referenced from Item 1.01). Warrant issuances are dilutive equity instruments and constitute material capital-raising activity that would affect investor assessment of ownership dilution and the registrant's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-03T11:02:09.082615+00:00","company_name":"Autolus Therapeutics plc","ticker":"AUTL","filing_date":"2026-08-03"}]}